The aim of this study was to evaluate the effect of topical administration of corticosteroid beclomethasone dipropionate on common nasal symptoms in moderate allergic and non-allergic hyperreactive eosinophilic rhinitis, and in allergic and non-allergic hyperreactive eosinophilic rhinitis associated with bilateral moderate nasal polyposis. The study was prospective and controlled. During the study 106 patients were examined, out of whom 66 were treated, while 40 had no therapy. Beclomethasone diproprionate nasal spray was administered in the daily dose of 400 micrograms. Patients with isolated rhinitis underwent 3 otorhinolaryngologic examinations during the six-week treatment. Patients with nasal polyposis underwent 4 otorhinolaryngologic examinations during six-month treatment. One-week therapy showed highly significant decrease of the average score of symptoms of isolated rhinitis in relation to basal condition. No further significant change was noted after six-week therapy. Six-week therapy of nasal polyposis exerted significantly reduced score of symptoms in relation to basic condition. During further treatment no significant reduction of symptoms was noted. Follow-up period of all control subgroups showed no significant change of symptom scores. Topical therapy with beclomethasone dipropionate represented a significant medication of the first therapeutic line in moderate isolated eosinophilic rhinitis, as well as in moderate bilateral eosinophilic nasal polyposis.

Download full-text PDF

Source
http://dx.doi.org/10.2298/vsp0301029uDOI Listing

Publication Analysis

Top Keywords

nasal polyposis
16
beclomethasone dipropionate
12
eosinophilic rhinitis
12
topical administration
8
allergic non-allergic
8
non-allergic hyperreactive
8
hyperreactive eosinophilic
8
therapy beclomethasone
8
isolated rhinitis
8
underwent otorhinolaryngologic
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!